TAS 102(also known as TAS-102, Tipiracil-trifluridine Mixture, Trifluridine-tipiracil hydrochloride mixture) is an orally active thymidine phosphorylase inhibitor and antimetabolite agent comprised of trifluridine, a thymidine-based nucleoside analogue, and tipiracil, a potent thymidine phosphorylase inhibitor. It is used for the treatment of metastatic colorectal cancer.
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.